Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.61 |
| ▸ | CA2 | P00918 | 9/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | GLA | P06280 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | CFTR | P13569 | 1/20 | 0.61 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | CDC42 | P60953 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693255 | 0.86 | PTGS2 (0.55) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL11066334 | 0.82 | RIPK1 (0.50) | L3MBTL1KDM4EALDH1A1MAPTGLA | |
| SCHEMBL27547538 | 0.78 | CA1 (0.45) | CA1CA2ALDH1A1PDE5A | |
| SCHEMBL3679184 | 0.78 | SMN1; SMN2 (0.52) | CA1CA2ALDH1A1MAPTATM | |
| SCHEMBL25370685 | 0.78 | MAPT (0.62) | CA1CA2L3MBTL1ALDH1A1GAA | |
| SCHEMBL14484122 | 0.76 | CA1 (1.00) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL27556930 | 0.75 | RIPK1 (0.44) | ALDH1A1 | |
| SCHEMBL5857979 | 0.75 | PTGS2 (0.69) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4020011 | 0.74 | PTGS2 (0.76) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5856375 | 0.74 | CA1 (0.66) | CA1CA2L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1698602-A | Usage of pyrazoline derivant in the drug preparation for preventing and/or treating cell breeding disease | ESTEVE LABOR DR (ES) | 2005-11-23 | — | — | CN | claimed |
| EP-1516621-A2 | Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-03-23 | — | — | EP | claimed |
| CN-1189459-C | Pyrazoline derivatives, process for their preparation and their use as medicaments | ESTEVE LABOR DR (ES) | 2005-02-16 | — | — | CN | claimed |
| CN-1509171-A | Use of pyrazoline derivatives for the preparation of a medicament for the prevention and/or treatment of cell proliferative diseases | ��˹���IJ�ʿʵ���ҹɷ�����˾ | 2004-06-30 | — | — | CN | claimed |
| EP-1083171-B1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2004-04-28 | — | — | EP | claimed |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-02-19 | — | — | US | claimed |
| EP-1384477-A1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-01-28 | — | — | EP | claimed |
| CN-1307566-A | Pyrazoline derivatives, their prep. and application as medicaments | ESTEVE LABOR DR (ES) | 2001-08-08 | — | — | CN | claimed |
| EP-1083171-A1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | VHL, MET, PRMT1 | CA1 911/4885CA2 1414/4885L3MBTL1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.